In the News
Welcome to our news archive, your resource for company announcements, press releases, and media coverage. Here you’ll find updates on our latest initiatives, strategic partnerships, and industry contributions, as well as background materials to support media inquiries. Explore past stories to see how we continue to shape conversations across healthcare and life sciences.
This episode of NPR’s Weekend Edition Sunday focuses on the telehealth companies hired by employers to minimize their spend on weight-loss related medications. NRP reached out to MMIT’s Chief Clinical Officer Jayne Hornung for her thoughts on how these platforms work to limit use of GLP-1s.
In March, Novo Nordisk’s patent on semaglutide expired in several countries, clearing the way for generics in the international market. Healthcare Brew asked MMIT CCO Jayne Hornung for her thoughts on what this development means for pricing trends, the U.S. market, and competitors like Eli Lilly.
At Asembia 2026, Pharmacy Podcast Network interviewed MMIT’s Andrew Rouff and The Dedham Group’s Hannah Baxter. Listen to this episode for Andrew’s thoughts on emerging technologies and the challenges facing patients and providers in the rare disease space. Hannah discusses how manufacturers and distributors can collaborate more effectively to improve patient outcomes and operational efficiency.
The FDA is attempting to shut down the black market for retatrutide, a pipeline treatment for obesity, type 2 diabetes and kidney and liver diseases that is still in final-phase testing. Investor’s Business Daily spoke to MMIT’s CCO Jayne Hornung about the black market, the drug’s potential for morbidly obese patients, and what’s likely to happen after FDA approval.
The success of the TrumpRx platform depends in large part on pharmacies’ willingness to accept lower reimbursement rates for drugs they’ve already purchased. MMIT’s Steve Callahan explained that as the program grows, pharmacies might reconsider their business model to ensure they can meet their own margins.
In an effort to reduce healthcare costs, the FDA would like many prescription medications to become over-the-counter products. MMIT’s Steve Callahan explains that while this move would theoretically improve patient access, patients would be responsible for the full cost of these treatments.